Current and emerging drugs for idiopathic pulmonary fibrosis

被引：21

作者：

Gharaee-Kermani, Mehrnaz ^{[1
]}

Hu, Biao ^{[1
]}

Thannickal, Victor J. ^{[1
]}

Phan, Sern. H. ^{[1
]}

Gyetko, Margaret R. ^{[1
]}

机构：

[1] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA

来源：

EXPERT OPINION ON EMERGING DRUGS | 2007年 / 12卷 / 04期

基金：

美国国家卫生研究院;

关键词：

angiogenesis; antifibrotic agents; anti-inflammatory agents; fibrocytes; idiopathic pulmonary fibrosis; IFN-gamma; inflammation; myofibroblasts; N-acetylcysteine; pathogenesis; pirfenidone; repair;

D O I：

10.1517/14728214.12.4.627

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Idiopathic pulmonary fibrosis is a chronic, progressive and often fatal form of interstitial lung disease. It is characterized by injury with loss of lung epithelial cells and abnormal tissue repair, resulting in abnormal accumulation of fibroblasts and myofibroblasts, deposition of extracellular matrix and distortion of lung architecture, leading to respiratory failure. This lethal lung disorder continues to pose major clinical challenges as an effective therapeutic regimen has yet to be developed. In this report, therapeutic strategies are reviewed, including the use of antifibrotic agents, inhibition of cytokines, leukotrienes and cytokines receptors, and molecular targeting of specific signaling pathways during fibrotic processes and angiogenesis. This article examines the body of evidence supporting present therapies and reviews the newer agents being tested in patients with idiopathic pulmonary fibrosis.

引用

页码：627 / 646

页数：20

共 200 条

[1] Treatment of idiopathic pulmonary fibrosis: Is there anything new? [J].

Abdelaziz, MM ;

Samman, YS ;

Wali, SO ;

Hamad, MMA .

RESPIROLOGY, 2005, 10 (03) :284-289

[2] Effect of pirfenidone against vanadate-induced kidney fibrosis in rats [J].

Al-Bayati, MA ;

Xie, Y ;

Mohr, FC ;

Margolin, SB ;

Giri, SN .

BIOCHEMICAL PHARMACOLOGY, 2002, 64 (03) :517-525

[3]

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, Am J Respir Crit Care Med, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]

[4] Pathogenetic pathways and novel pharmaco therapeutic targets in idiopathic pulmonary fibrosis [J].